Background: Idarucizumab is licensed to reverse dabigatran in life-threatening haemorrhage. Establishment of venous access can be challenging, and the intraosseous (IO) route is a potentially life-saving alternative. In this study, we compared the efficacy and safety of IO or intravenous (i.v.) idarucizumab for dabigatran reversal in a porcine polytrauma model. Methods: Male pigs (n¼21) received oral dabigatran etexilate (30 mg kg À1 bid) for 3 days. On the 4th day, animals received
Editor's key points
Dabigatran, a thrombin inhibitor, is increasingly used in patients with a risk for thromboembolic events, but increases the risk for bleeding in trauma settings. Intravenous administration of an antidote of dabigatran, idarucizumab, is frequently prohibited because of difficult i.v. access, and intraosseous idarucizumab administration might be a life-saving alternative. In a porcine polytrauma model, the efficacy and safety of intraosseous and i.v. idarucizumab administration for dabigatran reversal were comparable. Idarucizumab administration to reverse dabigatran may be considered as an alternative route in case of acute life-threatening haemorrhage.
Direct oral anticoagulants (DOACs) are effective alternatives to warfarin in primary and secondary prophylaxis of thromboembolic conditions. Clinical data indicate that DOACs are at least as effective as vitamin K antagonists for stroke prevention in patients with atrial fibrillation, with reduced rates of life-threatening bleeding. 1 Despite the therapeutic benefits, as with all anticoagulants, DOACs are associated with a risk of bleeding complications. Patients with trauma-related bleeding or a need for urgent invasive surgery may require emergency reversal of DOAC therapy. Idarucizumab is a specific reversal agent for the direct thrombin inhibitor (DTI) dabigatran. It binds exclusively to dabigatran with high affinity, providing rapid reversal of anticoagulation without affecting the coagulation cascade. 2 Preclinical and clinical studies have shown that idarucizumab is efficacious and well tolerated in emergency reversal of dabigatran.
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During life-threatening haemorrhage and shock, attaining vascular access for administration of haemostatic therapy can be challenging because of hypovolaemia and peripheral vasoconstriction. Additional complications may include obesity, peripheral oedema, damaged vascular structures, and traumatic amputations. Intraosseous (IO) administration may enable difficulties of vascular access to be avoided, and has been endorsed in trauma guidelines. 9 However, evidence supporting IO administration of haemostatic agents is limited. 10e14 It may be questioned whether the large molecular size of idarucizumab might limit transportation from the bone marrow to the plasma, and whether the antibody structure remains intact during this process. In this study, we investigated the efficacy and safety of IO vs i.v. administration of idarucizumab for dabigatran reversal in a lethal porcine polytrauma model. We also investigated fully automated thromboelastography as a tool for monitoring dabigatran and its reversal by idarucizumab.
15,16

Methods
Animals and ethics
The study was performed in 28 male German landrace pigs with mean bodyweight 43.2 kg [standard deviation (SD): 3.7 kg]. Permission was granted by the government office for animal care and use (Landesamt fü r Natur, Umwelt und Verbraucherschutz, Recklinghausen, Germany), and the study was performed in compliance with German legislation governing animal studies and the Animal Research: Reporting of in vitro Experiments (ARRIVE) guidelines. Before surgery, male German landrace pigs from a disease-free barrier breeding facility were housed in ventilated rooms and allowed to acclimatise to their surroundings for a minimum of 7 days. Animals were fasted overnight before surgical procedure, with water allowed ad libitum. Examination by a veterinarian ensured that the animals were in good health. The abdomen was reopened 12 min after liver injury to measure blood loss (intraperitoneal blood was suctioned into a pre-weighed container). A pre-weighed gauze was then applied as hepatic packing. At 15 min post-trauma, study treatment was administered by the investigator who was unaware of the study arm of each animal.
Dabigatran administration and idarucizumab preparation
Haemodynamic values, including cardiac output, pulmonary artery pressure, pulmonary wedge pressure, central venous pressure, and arterial pressure were monitored throughout the study. Blood samples were collected after dabigatran infusion and at 12, 30, 60, 120, and 240 min after trauma. Details of tests performed on blood samples are provided in the Supplementary material. Animals surviving for 240 min were euthanised. The abdomen was reopened immediately after death and the inferior vena cava was clamped. Total blood loss was calculated by weighing intraperitoneal blood and the gauze. The heart, lungs, liver, kidneys, and left tibia were removed for histopathologic examination (Supplementary material).
Thromboelastometry, thromboelastography, and thrombin generation
Thromboelastometry was performed on a ROTEM ® device (Tem International GmbH, Munich, Germany). EXTEM and INTEM assays were performed using citrated whole blood. Whole blood coagulation was also assessed using fully automated thromboelastography (TEG ® 6s Hemostasis Analyzer;
Haemonetics Corp., Braintree, MA, USA). Oral anticoagulant cartridges (provided for performance evaluation only) were used, with a specific DTI channel based on ecarin stimulation and a specific Factor Xa (FXa) inhibitor channel with human FXa as a coagulation stimulator. 15, 16 The reaction time (R, min;
time from start of assay to an amplitude of 2 mm) represented the initiation phase of clotting. Plasma thrombin generation was measured using a calibrated automated thrombogram (Thrombinoscope BV, The Netherlands).
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Statistical analysis
The sample size was calculated a priori for comparisons between groups based on a repeated measures analysis of variance, with blood loss as the primary endpoint. G*Power software (version 3.1.9.2) (Heinrich-Heine-Universit€ at, Dü sseldorf, Germany) was used for the calculation. Based on data from previous animal experiments, 5 ,20 a high effect size was estimated (f¼0.3). For a significance level of 0.05 with four study groups, a total sample size of 32 animals (eight animals per group) was sufficient to achieve a power of 0.92. However, because of ethical considerations and after an interim data analysis, the size of each group was reduced to seven animals. A repeated measure analysis of variance was used to compare study groups in relation to blood loss, coagulation variables, and hemodynamic variables, with intervention as group-factor and time as repeated-factor. To allow for variation in group differences over time, the group Â time interaction was included. To allow for multiple comparisons, the Sidak method was used post hoc. Survival data were analysed using pairwise log-rank tests. Statistical tests were performed two-tailed and P-values <0.05 were considered statistically significant. Correlations between dabigatran concentration and ROTEM/TEG 6s parameters were assessed by Pearson correlation coefficients. SPSS 23 (SPSS, Chicago, IL, USA) was used for statistical analysis. Data are presented as mean (SD), with n¼7 per group unless otherwise indicated.
Results
Impact of dabigatran anticoagulation
There were no clinically significant differences in baseline values between the three study groups receiving dabigatran ( 
Dabigatran concentrations and coagulation parameters
Fifteen minutes after idarucizumab administration, plasma dabigatran concentrations were not measurable in either the IO or the i.v. group, whereas mean dabigatran concentrations in control animals remained above 300 ng ml À1 throughout the experiment (Table 1) . After idarucizumab treatment, PT and aPTT values were comparable with sham group values. In the control group, PT and aPTT values were significantly prolonged from 30 min post-trauma, and the extent of prolongation increased over time (Table 1) . Plasma fibrinogen concentrations declined steeply after trauma but remained stable in the sham and idarucizumab groups until end of study. In contrast, with continued blood loss in the control group, plasma fibrinogen concentrations continued to decrease over time ( Table 1) . As expected in the sham group, concentrations of thrombin-antithrombin complexes (TAT) and D-dimers increased after trauma, indicating that coagulation was activated (Fig. 3) . Because of inhibition of coagulation, concentrations of TAT and D-dimers changed little after trauma in the control group. Administration of idarucizumab resulted in patterns reflecting those seen in the sham group.
Haemodynamics and blood cell count
Compared with the other study groups, heart rate was significantly increased and mean arterial pressure was significantly decreased in the control group post-trauma ( Supplementary  Fig. S1 ). In response to idarucizumab (either IO or i.v.), values for these parameters became comparable with those in sham animals. In the idarucizumab groups and sham animals, cardiac output was preserved, and only small changes in lactate concentrations occurred (Supplementary Fig. S1 ). In contrast, in the control group, significant decreases in cardiac output and significant increases in lactate concentrations were observed. Haemoglobin concentrations and platelet counts were reduced after trauma, with greater reductions in dabigatrantreated animals than sham animals. After IO or i.v. idarucizumab, haemoglobin concentrations and platelet counts changed little. However, in control animals, these variables declined significantly below the intervention and sham groups (Table 1) .
Viscoelastic coagulation assays
Minimal changes in ROTEM CT and TEG 6s R-time were observed in the sham group. Idarucizumab (either IO or i.v.) restored these variables to similarity with the sham group, and this was maintained until end of study. However, in the control group, EXTEM and INTEM CT increased progressively and, from 30 min post-trauma, were significantly higher than the values observed in the other groups (Fig. 1) . Also, continued deteriorations in R-time were observed in control animals. At 120 and 240 min, the extent of coagulopathy meant that some variables could not be determined in the control group.
The R-time measured on the specific DTI channel exhibited strong positive correlation with plasma dabigatran concentrations after both i.v. and IO idarucizumab (Pearson's correlation coefficient, R¼0.90 and R¼0.89, respectively; Fig. 4 ). However, this correlation was not observed in the control group. Similar results were obtained with CT in the EXTEM and INTEM thromboelastometry assays (Fig. 4) .
Thrombin generation
Values for lag time, peak height, and endogenous thrombin potential (ETP) changed little in the sham group (Fig. 2) . Dabigatran anticoagulation significantly lowered peak height and ETP values compared with the sham animals. In animals receiving idarucizumab (both IO and i.v.), at 30 min posttrauma, values for peak height and ETP were comparable with the sham group and there was no overcorrection. Subsequently, peak height and ETP decreased in both idarucizumab groups, reaching values significantly lower than in the sham group from 60 min and 120 min post-trauma, respectively. In the control group, peak height and ETP were significantly lower than in all other study groups, from 30 min post-trauma onwards. Dabigatran anticoagulation was associated with a modest increase in lag time. This was reversed in both idarucizumab groups, and lag time remained similar in these groups to the sham group from 30 min post-trauma onwards. However, lag time increased over time in the control group and was significantly higher than in the other groups at 60 min (Fig. 2) .
Histopathologic examination
All organs showed normal macroscopic anatomical structure except at the liver laceration and the bone injection sites. In non-injured liver tissue and in the heart, lungs, and kidneys, there was no macroscopic or microscopic evidence of thromboembolic events. Bones at injection sites showed a cystic space at the needle tip. At the pseudocystic wall, normal fatty bone marrow with some haematopoietic cells could be seen. The adjacent bone marrow containing bone trabeculae revealed vital haematopoietic marrow and fatty tissue. Around the trabeculae reaching from the centre to the initial compact bone, free spaces were visible (most likely because of displacement of the liquids infused; Supplementary Fig. S2 ). There were no differences between study groups in histopathologic findings, and no necrosis was detected.
Discussion
This preclinical study is the first to show that administration of IO idarucizumab is as effective in reducing blood loss related to dabigatran anticoagulation as i.v. idarucizumab. Reversal of dabigatran anticoagulation was rapid and well tolerated with either route, with no differences in attenuation of blood loss or correction of coagulation test results. The rapid reduction of dabigatran anticoagulation with both administration methods shows that IO idarucizumab entered the plasma and bound to dabigatran in a similar manner to i.v. administration. There was no evidence of thromboembolic events with either IO or i.v. idarucizumab. These outcomes are of high importance in patients with massive bleeding and haemorrhagic shock, because establishment of i.v. access can be difficult and the availability of an alternative route could be life-saving. Dabigatran functions by binding to thrombin and inhibiting its action, effectively blocking progression of the coagulation cascade. Idarucizumab binds to dabigatran with very high affinity, resulting in the prevention of dabigatran binding to thrombin. Provided that the dose of idarucizumab is sufficient to bind all dabigatran molecules in circulation, the anticoagulant effect of dabigatran is reversed. 2 Three further studies have been performed using porcine models. In one of these studies, IO and i.v. tranexamic acid were found to be equivalent. 10 Similarly, the efficacy of fibrinogen concentrate was shown to be similar when administered IO or i.v. 13 The third study used a haemorrhagic shock model, and the bioavailability and toxicity of IO and i.v. recombinant activated FVII (rFVIIa) were similar. 14 This last study is of particular interest because of similarities between rFVIIa and idarucizumab in molecular size (~50 kDa vs 48 kDa). Trauma guidelines support the IO route for delivering resuscitation drugs in adult and paediatric patients if i.v. cannulation attempts fail. 9, 25, 26 In emergency situations, accurate assessment of anticoagulation may help determine the reversal strategy. Although the diluted thrombin time measures the plasma dabigatran concentration, a long turnaround time and limited availability in emergency settings are significant drawbacks. 27 Thrombin time is another potential candidate for determining dabigatran concentrations, but it is highly sensitive to dabigatran and, with a low upper limit of quantification, is more suitable for estimating very low concentrations. Viscoelastic coagulation monitoring has shown potential value, with CT in the INTEM and EXTEM assays providing an indication of dabigatran anticoagulation. 17, 20, 27, 28 However, these variables are not specific to DOACs and are affected by deficiencies in coagulation factors (e.g. hypofibrinogenaemia) or thrombin generation. 29 In contrast, TEG 6s cartridges containing ecarin and human factor Xa as activators have been validated for specific measurement of DTIs and AFXa medications, respectively. 15, 16 In our study, DTI channel R-time correlated strongly with the concentrations of dabigatran, although this was not observed in the control group (perhaps because of extensive bleeding). Clotting in both the DTI and AFXa assays depends on fibrinogen and prothrombin; major depletion of these coagulation factors can limit the value of these assays. Therefore, TEG 6s assessment of DOAC activity may be limited in patients with severe coagulopathy.
Limitations of the animal model used in this study, such as species differences between pigs and humans, have been explored previously. 17 Strengths of our study include prior work in establishing the model, and inclusion of both a control and a sham group.
In conclusion, IO idarucizumab was as effective and well tolerated for dabigatran reversal as i.v. idarucizumab in this porcine trauma model. In all animals treated with idarucizumab, the effects of dabigatran on coagulation parameters were reversed, whereas the coagulation status in control animals continued to deteriorate over time. IO administration of idarucizumab might be a valuable option in patients with limited venous access. Fully automated thromboelastography with DOAC-specific cartridges appears to be a promising means of assessing dabigatran activity for guidance of reversal in bleeding patients. However, this methodology is not yet available in clinical practice. Currently available thromboelastometry or thromboelastography tests are less specific but still provide useful data for guiding anticoagulation reversal.
